Faculty Information - Mineki Saito

Present specialized field

BooK

Journal

Presentation

Belonging society

（Last updated : 2022-06-02 09:37:03）

Mineki Saito
Department Kawasaki Medical School Kawasaki Medical School, Department of Microbiology,

Position Professor

■ Present specialized field

Virology, Immunology, Neurology (Key Word：Human T-cell leukemia virus type-1, HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP), Influenza viruses)

■ BooK

1.	2016/11	HTLV-1, Reference Module in Life Sciences
2.	2013/12	The method of making vacuum-packed specimens easy to carry around or circulate a large-sized parasite
3.	2012/02	HTLV-1, Brenner's Online Encyclopedia of Genetics
4.	2007/06	Virus-host interactions and its implication in the development of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), Current Topics in Neuroimmunology

■ Journal

1.	2019/05	Association Between HTLV-1 Genotypes and Risk of HAM/TSP.
2.	2019/03	Association of high levels of plasma OX40 with acute adult T-cell leukemia.
3.	2017/09	Intracellular morphological changes in Staphylococcus aureus induced by treatment with sodium hypochlorite.
4.	2017/07	Prevalence of plasma autoantibody against cancer testis antigen NY-ESO-1 in HTLV-1 infected individuals with different clinical status.
5.	2017/04	Establishment of the complete life cycle of Spirometra (Cestoda: Diphyllobothriidae) in the laboratory using a newly isolated triploid clone
6.	2014/09	The neutralizing function of the anti-HTLV-1 antibody is essential in preventing in vivo transmission of HTLV-1 to human T cells in NOD-SCID/gamma-c-null (NOG) mice.
7.	2017/03	Influenza A virus hemagglutinin and neuraminidase act as novel motile machinery.
8.	2014/06	Pathogenic conversion of forkhead box protein 3-positive T cells into T helper 17 cells: Is this also the case for multiple sclerosis?
9.	2014/06	Elimination of human T cell leukemia virus type-1 (HTLV-1)-infected cells by neutralizing and ADCC-inducing antibodies against HTLV-1 envelope gp46.
10.	2013/09	A novel and simple method for generation of human dendritic cells from unfractionated peripheral blood mononuclear cells within 2 days: its application for induction of HIV-1-reactive CD4(+) T cells in the hu-PBL SCID mice.
11.	2014/04	Neuroimmunological aspects of human T cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis.
12.	2013/05	Increased expression of OX40 is associated with progressive disease in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis.
13.	2012/04	HTLV-1 Infection and its Associated Diseases.
14.	2021/06/04	Development of multiplexing gene silencing system using conditionally induced polycistronic synthetic antisense RNAs in Escherichia coli.
15.	2021/05/24	Development of a Genetically Stable Live Attenuated Influenza Vaccine Strain Using an Engineered High-Fidelity Viral Polymerase
16.	2021/03/16	Genome wide association study of HTLV-1-associated myelopathy/tropical spastic paraparesis in the Japanese population
17.	2020/09/24	Antimicrobial antisense RNA delivery to F-pili producing multidrug-resistant bacteria via a genetically engineered bacteriophage.
18.	2020/07/15	Inhibition of ABL1 tyrosine kinase reduces HTLV-1 proviral loads in peripheral blood mononuclear cells from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis.
19.	2019/04	Diversity of cell phenotypes among MT-2 cell lines affects the growth of U937 cells and cytokine production.
20.	2019	Tyr82 Amino Acid Mutation in PB1 Polymerase Induces an Influenza Virus Mutator Phenotype
21.	2018/11	Distinct gene expression signatures induced by viral transactivators of different HTLV-1 subgroups that confer a different risk of HAM/TSP
22.	2018/01	Unique directional motility of influenza C virus controlled by its filamentous morphology and short-range motions
23.	2017/12	The CC chemokine ligand (CCL) 1, upregulated by the viral transactivator Tax, can be downregulated by minocycline: possible implications for long-term treatment of HTLV-1-associated myelopathy/tropical spastic paraparesis.
24.	2017/03	Inhibitory effects of dietary soyasaponin on 2,4-dinitrofluorobenzene-induced contact hypersensitivity in mice
25.	2017	Generation of a Genetically Stable High-Fidelity Influenza Vaccine Strain.
26.	2016/08	Re-emergence of H3N2 strains carrying potential neutralizing mutations at the N-linked glycosylation site at the hemagglutinin head, post the 2009 H1N1 pandemic.
27.	2016/04	Absolute quantification of HTLV-1 basic leucine zipper factor (HBZ) protein and its plasma antibody in HTLV-1 infected individuals with different clinical status.
28.	2016/02	HTLV-1 subgroups associated with the risk of HAM/TSP are related to viral and host gene expression in peripheral blood mononuclear cells, independent of the transactivation functions of the viral factors.
29.	2012/04	Immunopathogenesis of Human T-cell leukemia virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP): Recent perspectives
30.	2011/10	Identification of an unique CXCR4 epitope whose ligation inhibits infection by both CXCR4 and CCR5 tropic human immunodeficiency type-I viruses.
31.	2010/10	Opposite effects of two nonstructural proteins of Theiler's murine encephalomyelitis virus regulates apoptotic cell death in BHK-21 cells.
32.	2010/10	Suppression of CCR5-tropic HIV type 1 infection by OX40 stimulation via enhanced production of beta-chemokines.
33.	2010/08	Activation of the PI3K-Akt pathway by human T cell leukemia virus type 1 (HTLV-1) oncoprotein Tax increases Bcl3 expression, which is associated with enhanced growth of HTLV-1-infected T cells.
34.	2010/03	Impairment of in vitro generation of monocyte-derived human dendritic cells by inactivated human immunodeficiency virus-1: Involvement of type I interferon produced from plasmacytoid dendritc cells.
35.	2010/02	Immunogenetics and the pathological mechanisms of human T-cell leukemia virus type 1- (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
36.	2009/05	Immunogenetics of human T-cell leukemia virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
37.	2009/04	Different subcellular localization of Theiler's murine encephalomyelitis virus leader proteins of GDVII and DA strains in BHK-21 cells.
38.	2009/02	In vivo expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP).
39.	2008/09	Impaired function of human T-lymphotropic virus type 1 (HTLV-1)-specific CD8+ T cells in HTLV-1-associated neurologic disease.
40.	2008/04	Significantly increased antibody response to heterogeneous nuclear ribonucleoproteins in cerebrospinal fluid of multiple sclerosis patients but not in patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.
41.	2008/03	Increased frequency of CD4+T cells expressing fractalkine receptor CX3CR1 in patients with HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP), but its AIDS susceptible polymorphisms are not associated with the disease.
42.	2008/01	Inclusion body myositis associated with human T-lymphotropic virus-type I infection: eleven patients from an endemic area in Japan.
43.	2007/12	Ex vivo analysis of human T cell lymphotropic virus type-1 (HTLV-1) specific CD4+ cells using MHC class II tetramer composed of neurological disease susceptive allele and its immunodominant peptide.
44.	2007/06	Abnormalities of spinal magnetic resonance images implicate clinical variability in human T-cell lymphotropic virus type I-associated myelopathy.
45.	2006/07	Flow cytometry evaluation of the T-cell receptor Vbeta repertoire among human T-cell lymphotropic virus type-1 (HTLV-1) infected individuals: effect of interferon alpha therapy in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
46.	2006/06	Clinical symptoms and the odds of human T-cell lymphotropic virus type 1-associated myelopathy/ tropical spastic paraparesis (HAM/TSP) in healthy virus carriers: application of best-fit logistic regression equation based on host genotype, age, and provirus load.
47.	2006/03	Geographical distribution and disease associations of the CD45 exon 6 138G variant
48.	2006/02	Chronic progressive sensory ataxic neuropathy associated with limited systemic sclerosis.
49.	2006/01	Genetic variability in the extracellular matrix protein as a determinant of risk for developing HTLV-I-associated neurological disease
50.	2005/10	A prospective uncontrolled trial of fermented milk drink containing viable Lactobacillus casei strain Shirota in the treatment of HTLV-1 associated myelopathy/tropical spastic paraparesis
51.	2005/10	Human T cell leukemia virus type I-infected patients with Hashimoto's thyroiditis and Graves' disease
52.	2005/05	ApaI polymorphism of vitamin D receptor gene is associated with susceptibility to HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) in HTLV-1 infected individuals
53.	2005/03	Differences in viral and host genetic risk factors for development of human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis between Iranian and Japanese HTLV-1-infected individuals
54.	2004/11	Adult T-cell leukemia predominantly involving exocrine glands
55.	2004/11	Longer dinucleotide repeat polymorphism in matrix metalloproteinase-9 (MMP-9) gene promoter which correlates with higher HTLV-I Tax mediated transcriptional activity influences the risk of HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP)
56.	2004/10	Chronic progressive cervical myelopathy with HTLV-I infection: Variant form of HAM/TSP?
57.	2004/10	Polymorphism in the interleukin-10 promoter affects both provirus load and the risk of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis
58.	2004/10	The role of CTLs in persistent viral infection: cytolytic gene expression in CD8+ lymphocytes distinguishes between individuals with a high or low proviral load of human T cell lymphotropic virus type 1
59.	2004/04	Serum concentration and genetic polymorphism in the 5'-untraslated region of VEGF is not associated with susceptibility to HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP) in HTLV-I infected individuals
60.	2004/01	Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-alpha therapy for HTLV-I-associated myelopathy/tropical spastic paraparesis
61.	2003/11	A C77G point mutation in CD45 exon 4, which is associated with the development of multiple sclerosis and increased susceptibility to HIV-1 infection, is undetectable in Japanese population
62.	2003/07	Low frequency of CD94/NKG2A-positive T lymphocytes in HTLV-1 associated myelopathy/tropical spastic paraparesis patients but not in asymptomatic carriers
63.	2003/04	Different cytokine production in tax-expressing cells between patients with human T cell lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis and asymptomatic HTLV-I carriers
64.	2003/01	Gap junction protein beta 1 (GJB1) mutations and central nervous system symptoms in X-linked Charcot-Marie-Tooth disease
65.	2002/12	Miyoshi myopathy patients with novel 5' splicing donor site mutations showed different dysferlin immunostaining at the sarcolemma
66.	2002/11	Molecular analysis of T cell clonotypes in muscle-infiltrating lymphocytes from patients with human T lymphotropic virus type 1 polymyositis
67.	2002/06	Inhibition of the tax-dependent human T-lymphotropic virus type I replication in persistently infected cells by the fluoroquinolone derivative k-37
68.	2001/01	In vivo selection of T-cell receptor junctional region sequences by HLA-A2 human T-cell lymphotropic virus type 1 Tax11-19 peptide complexes
69.	2000/11	Fratricide among CD8(+) T lymphocytes naturally infected with human T cell lymphotropic virus type I
70.	2000/04	An overexpression of fibroblast growth factor (FGF) and FGF receptor 4 in a severe clinical phenotype of facioscapulohumeral muscular dystrophy
71.	2000/02	Abundant tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes
72.	1999/10	Gene for hereditary motor and sensory neuropathy (proximal dominant form) mapped to 3q13.1
73.	1999/10	Hereditary motor and sensory neuropathy with proximal dominant involvement: clinical, pathological, and genetic features
74.	1999/08	Increased levels of soluble Fas ligand in CSF of rapidly progressive HTLV-1-associated myelopathy/tropical spastic paraparesis patients
75.	1999/04	A novel MPZ gene mutation in dominantly inherited neuropathy with focally folded myelin sheaths
76.	1999/02	Localized scleroderma associated with progressing ischemic stroke
77.	1998/11	Atypical rigid form of Huntington's disease: a case with peripheral amyotrophy and congenital defects of a lower limb
78.	1998/10	Predominant expression of Fas ligand mRNA in CD8+ T lymphocytes in patients with HTLV-1 associated myelopathy
79.	1998/09	Afterdischarges following F waves observed in a patient with tetanus
80.	1996/10	Mutation rates in LTR of HTLV-1 in HAM/TSP patients and the carriers are similarly high to Tax/Rex-coding sequence
81.	1995/09	Frequent mutation in pX region of HTLV-1 is observed in HAM/TSP patients, but is not specifically associated with the central nervous system lesions
82.	1993/12	Nucleotide sequence analysis of HTLV-I isolate from a Korean patient with HAM/TSP
Display 5 items
Display all(82)

■ Presentation

1.	2014/05/23	Screening of drugs and antibodies using in vitro systems for treatment of HAM （Speech，General）
2.	2013/06/27	Complete prevention of HTLV-1 infection in humanized mice (hu-PBL SCID) by a neutralizing monoclonal antibody to envelope gp46. （Speech，General）
3.	2019/08/25	Association Between HTLV-1 Genotypes and Risk of HAM/TSP. （Speech，General）
4.	2018/09/16	Directional Motility of influenza C virus （Poster notice，General）
5.	2018/08/23	Establishment of a newly isolated triploid clone of Spirometra (Cestoda: Diphyllobothriidae) as a powerful tool for studying the molecular and cellular bases of sparganosis （Speech，General）
6.	2018/03/18	Establishment of the complete life cycle of Spirometra (Cestoda: Diphyllobothriidae) in the laboratory using a newly isolated triploid clone （Speech，General）
7.	2017/09/20	Motility of filamentous influenza virus （Poster notice，General）
8.	2017/03/10	Establishment of a novel small animal model for HAM/TSP （Speech，Panelist at Symposium/Workshop (Applied)）
9.	2017/03/08	Molecular analysis of HTLV-1 subgroups associated with the development of HAM/TSP （Poster notice，Panelist at Symposium/Workshop (Applied)）
10.	2017/03/08	Plasma autoantibody against cancer testis antigen NY-ESO-1 in HTLV-1 infected individuals with different clinical status （Poster notice，Panelist at Symposium/Workshop (Applied)）
11.	2017/03/08	The role of CC chemokine ligand (CCL) 1 targeted by Tax in HAM/TSP （Poster notice，General）
12.	2016/11/26	Motile mechanism of influenza C virus （Poster notice，General）
13.	2016/10/23	Motile mechanism of influenza C virus （Poster notice，General）
14.	2016/05/14	The effect of soyasaponin diets on contact hypersensitivity in mice （Speech，General）
15.	2015/11/23	Detection of high titers of plasma anti-HBZ antibodies in HAM patients is independent of mRNA and protein levels in PBMCs （Speech，General）
16.	2015/06/18	Molecular and clinical analyses of HTLV-1 subgroups associated with the risk of developing HAM/TSP. （Poster notice，Panelist at Symposium/Workshop (Applied)）
17.	2015/05/22	A novel role for influenza virus neuraminidase in virus motility （Speech，General）
18.	2014/09/11	The mechanism of bactericidal action of sodium hypochlorite against Staphylococcus aureus （Poster notice，General）
19.	2013/06/05	Sodium hypochlorite degrades Staphylococcus aureus chromosomal DNA （Poster notice，General）
20.	2012/06/01	Complete prevention of HTLV-1 infection in humanized mice by a neutralizing monoclonal antibody to envelope gp46. （Speech，General）
Display 5 items
Display all(20)

■ Belonging society

1.	2001/01～	American Society for Microbiology
2.	2006/04～	International Society for NeuroVirology
3.	2008/04～	∟ Board of Directors